PRCP Human
HEK293 Cells.
Angiotensinase-C, PRCP, Proline Carboxypeptidase.
Greater than 95% as determined by SDS-PAGE.
Description
PRCP Human Recombinant produced in HEK cells is a single, glycosylated, polypeptide chain (22-496 a.a) containing a total of 481 amino acids, having a molecular mass of 54.3 kDa.
PRCP is fused to a 6 amino acid His-tag at C-terminus,and is purified by proprietary chromatographic techniques.
Product Specs
Angiotensinase-C, PRCP, Proline Carboxypeptidase.
HEK293 Cells.
LRPALRALGS LHLPTNPTSL PAVAKNYSVL YFQQKVDHFG FNTVKTFNQR YLVADKYWKK NGGSILFYTG NEGDIIWFCN NTGFMWDVAE ELKAMLVFAE HRYYGESLPF GDNSFKDSRH LNFLTSEQAL ADFAELIKHL KRTIPGAENQ PVIAIGGSYG GMLAAWFRMK YPHMVVGALA ASAPIWQFED LVPCGVFMKI VTTDFRKSGP HCSESIHRSW DAINRLSNTG SGLQWLTGALHLCSPLTSQD IQHLKDWISE TWVNLAMVDY PYASNFLQPL PAWPIKVVCQ YLKNPNVSDS LLLQNIFQAL NVYYNYSGQV KCLNISETAT SSLGTLGWSY QACTEVVMPF CTNGVDDMFE PHSWNLKELS DDCFQQWGVR PRPSWITTMY GGKNISSHTN IVFSNGELDP WSGGGVTKDI TDTLVAVTIS EGAHHLDLRT KNALDPMSVL LARSLEVRHM KNWIRDFYDS AGKQ HHHHHH
Product Science Overview
PRCP is a serine protease that cleaves off C-terminal amino acid residues adjacent to a proline. It is found in the central nervous system and peripheral tissues such as the kidney, placenta, lung, and liver . The enzyme was initially named angiotensinase C due to its ability to convert the vasoconstrictive angiotensin II to angiotensin 1-7, which causes vasodilatation . Additionally, PRCP inactivates angiotensin III, facilitates the autoactivation of prekallikrein, and truncates des-Arg 9-bradykinin and α-melanocyte stimulating hormone 1-13 (α-MSH 1-13) .
- Blood Pressure Regulation: PRCP converts angiotensin II, a potent vasoconstrictor, into angiotensin 1-7, which has vasodilatory effects. This conversion helps in regulating blood pressure and preventing hypertension .
- Body Weight and Metabolism: PRCP truncates α-MSH 1-13, an anorexigenic neuromodulator, into an inactive form called α-MSH 1-12, which does not evoke satiety. This effect is believed to take place at the site of hypothalamic neurons . Recent studies have shown that PRCP inhibitors can decrease food intake, suggesting that PRCP also truncates peripherally acting peptides involved in body weight regulation .
- Metabolic Disorders: A link between PRCP protein concentrations in plasma and metabolic disorders has been reported. PRCP activity in the circulation is correlated with body weight and adipose tissue in lean and obese subjects . PRCP activity increases with rising body mass index (BMI) and decreases upon weight loss .
Research on PRCP has shown its potential as a therapeutic target for various conditions:
- Obesity: PRCP’s role in truncating α-MSH 1-13 and its involvement in body weight regulation make it a potential target for obesity treatment. Small molecule PRCP inhibitors that act peripherally have been shown to decrease food intake in experimental animals .
- Hypertension: By converting angiotensin II into angiotensin 1-7, PRCP can help alleviate hypertensive cardiac remodeling and other detrimental effects of prolonged angiotensin II activation .
Recombinant human PRCP is produced for research purposes to better understand its physiological roles and therapeutic potential. The enzyme is characterized and validated using various biochemical assays, including reversed-phase high-performance liquid chromatography (RP-HPLC) and enzyme-linked immunosorbent assay (ELISA) .
